Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Jacobio Pharmaceuticals has reached a significant milestone by completing the first patient dosage in the Phase I/IIa clinical trial of its pan-KRAS inhibitor, JAB-23E73, in China. This innovative oral drug aims to target KRAS mutations found in a substantial percentage of cancer patients worldwide, with promising preclinical results. Investors may find Jacobio’s continued advancement in drug development noteworthy as the company strives for global leadership in innovative cancer treatments.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.